See more : E-World Co.,Ltd. (084680.KS) Income Statement Analysis – Financial Results
Complete financial analysis of AbbVie Inc. (4AB.DU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AbbVie Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Enel SpA (ESOCF) Income Statement Analysis – Financial Results
- Teléfonos de México, S.A.B. de C.V. (TMXLF) Income Statement Analysis – Financial Results
- The Yokohama Rubber Co., Ltd. (YORUF) Income Statement Analysis – Financial Results
- Suncorp Group Limited (SNMCY) Income Statement Analysis – Financial Results
- Xvivo Perfusion AB (publ) (XVIPY) Income Statement Analysis – Financial Results
AbbVie Inc. (4AB.DU)
About AbbVie Inc.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.32B | 58.05B | 56.20B | 45.80B | 33.27B | 32.75B | 28.22B | 25.64B | 22.86B | 19.96B | 18.79B | 18.38B | 17.44B | 15.64B | 14.21B |
| Cost of Revenue | 20.42B | 17.41B | 17.45B | 15.39B | 7.44B | 7.72B | 7.04B | 5.83B | 4.50B | 4.43B | 4.58B | 4.51B | 4.64B | 4.29B | 4.06B |
| Gross Profit | 33.90B | 40.64B | 38.75B | 30.42B | 25.83B | 25.04B | 21.18B | 19.81B | 18.36B | 15.53B | 14.21B | 13.87B | 12.80B | 11.35B | 10.16B |
| Gross Profit Ratio | 62.42% | 70.00% | 68.96% | 66.41% | 77.64% | 76.44% | 75.05% | 77.25% | 80.31% | 77.83% | 75.62% | 75.47% | 73.40% | 72.55% | 71.46% |
| Research & Development | 8.45B | 6.51B | 7.08B | 6.56B | 6.41B | 10.33B | 4.98B | 4.37B | 4.29B | 3.30B | 2.86B | 2.78B | 2.62B | 2.50B | 1.71B |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.87B | 15.26B | 12.35B | 11.30B | 6.94B | 7.40B | 6.28B | 5.86B | 6.39B | 7.72B | 5.35B | 4.99B | 5.89B | 3.82B | 3.35B |
| Other Expenses | -179.00M | -2.45B | -2.50B | -5.61B | -3.01B | -18.00M | -513.00M | -232.00M | -13.00M | 27.00M | 1.00M | 9.00M | 0.00 | 61.00M | 0.00 |
| Operating Expenses | 21.15B | 21.83B | 19.87B | 17.86B | 12.46B | 18.23B | 11.26B | 10.22B | 10.67B | 11.77B | 8.21B | 7.77B | 8.51B | 6.32B | 5.06B |
| Cost & Expenses | 41.56B | 39.24B | 37.31B | 33.24B | 19.90B | 25.95B | 18.30B | 16.05B | 15.17B | 16.20B | 12.79B | 12.28B | 13.15B | 10.61B | 9.11B |
| Interest Income | 540.00M | 186.00M | 39.00M | 174.00M | 275.00M | 204.00M | 146.00M | 82.00M | 33.00M | 38.00M | 21.00M | 20.00M | 20.00M | 28.00M | 0.00 |
| Interest Expense | 2.22B | 2.23B | 2.38B | 2.28B | 1.51B | 1.14B | 1.00B | 965.00M | 686.00M | 391.00M | 278.00M | 104.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.70B | 8.47B | 8.52B | 6.47B | 2.02B | 1.77B | 1.50B | 1.19B | 836.00M | 786.00M | 897.00M | 1.15B | 1.27B | 1.18B | 697.49M |
| EBITDA | 17.17B | 24.17B | 23.93B | 12.32B | 12.23B | 8.31B | 10.38B | 10.12B | 8.20B | 4.79B | 6.53B | 6.98B | 4.94B | 6.02B | 5.80B |
| EBITDA Ratio | 31.61% | 33.86% | 29.16% | 15.17% | 41.47% | 22.15% | 37.55% | 39.34% | 35.13% | 24.01% | 34.03% | 39.63% | 35.49% | 40.31% | 34.83% |
| Operating Income | 12.76B | 18.12B | 17.92B | 11.36B | 12.98B | 6.38B | 9.59B | 9.38B | 7.54B | 3.41B | 5.66B | 5.82B | 3.62B | 4.72B | 4.93B |
| Operating Income Ratio | 23.49% | 31.21% | 31.89% | 24.81% | 39.03% | 19.49% | 33.99% | 36.60% | 32.97% | 17.09% | 30.14% | 31.65% | 20.76% | 30.16% | 34.70% |
| Total Other Income/Expenses | -6.51B | -4.64B | -4.94B | -7.97B | -4.56B | -1.19B | -1.82B | -1.46B | -892.00M | -1.04B | -332.00M | -92.00M | 48.00M | 119.00M | 1.02B |
| Income Before Tax | 6.25B | 13.48B | 12.99B | 3.40B | 8.43B | 5.20B | 7.73B | 7.88B | 6.65B | 2.37B | 5.33B | 5.73B | 3.67B | 4.84B | 5.95B |
| Income Before Tax Ratio | 11.51% | 23.21% | 23.11% | 7.42% | 25.33% | 15.87% | 27.39% | 30.75% | 29.07% | 11.87% | 28.38% | 31.15% | 21.03% | 30.92% | 41.86% |
| Income Tax Expense | 1.38B | 1.63B | 1.44B | -1.22B | 544.00M | -490.00M | 2.42B | 1.93B | 1.50B | 595.00M | 1.20B | 450.00M | 235.40M | 658.00M | 1.31B |
| Net Income | 4.86B | 11.84B | 11.54B | 4.62B | 7.88B | 5.69B | 5.31B | 5.95B | 5.14B | 1.77B | 4.13B | 5.28B | 3.43B | 4.18B | 4.64B |
| Net Income Ratio | 8.95% | 20.39% | 20.54% | 10.08% | 23.69% | 17.36% | 18.82% | 23.22% | 22.50% | 8.89% | 21.97% | 28.70% | 19.68% | 26.72% | 32.62% |
| EPS | 2.73 | 6.65 | 6.53 | 2.62 | 5.33 | 3.85 | 3.33 | 3.74 | 3.20 | 1.11 | 2.60 | 3.35 | 2.12 | 2.59 | 2.87 |
| EPS Diluted | 2.72 | 6.63 | 6.45 | 2.62 | 5.31 | 3.68 | 3.30 | 3.63 | 3.13 | 1.10 | 2.56 | 3.35 | 2.11 | 2.57 | 2.85 |
| Weighted Avg Shares Out | 1.77B | 1.77B | 1.77B | 1.77B | 1.48B | 1.48B | 1.59B | 1.59B | 1.61B | 1.59B | 1.59B | 1.58B | 1.62B | 1.62B | 1.62B |
| Weighted Avg Shares Out (Dil) | 1.77B | 1.78B | 1.78B | 1.77B | 1.48B | 1.55B | 1.60B | 1.63B | 1.64B | 1.61B | 1.60B | 1.58B | 1.63B | 1.63B | 1.63B |
Source: https://incomestatements.info
Category: Stock Reports